International Cooperation -...
Transcript of International Cooperation -...
1
Based on working documents – refer to final published call text
International Cooperationin Health Research and Life Sciences
Modalities and Topics of next Call
Open Information Day – Brussels, 8 June 2010
Dr Gianpietro van de GoorDirectorate Health, DG Research
European Commission
2
Based on working documents – refer to final published call text
International Research Collaborations
Priority for the EU - Opportunity for Researchers
Diseases do not respect political or cultural borders, and affect both poor and rich countriesHealth is a political priority for most countries(rich and poor) “Rich world” diseases (cancer, diabetes, cardivascular diseases, …) also affect developing countries and vice-versa (Malaria, TB, …)Treatments and cures are universal (public good)
3
Based on working documents – refer to final published call text
International Research Collaborations
Priority for the EU - Opportunity for Researchers
Access and integration of expertise (people) and know-how (methodologies and technologies)Networking, Division of Tasks, Pooling of resources(knowledge, infrastructures, investments)
Improving health of European citizens and/or increasing competitiveness of European health-related companies
Alignment of efforts on common goals with mutual benefits
Addressing common global health threats (communicable diseases, (re)emerging epidemics, public health systems in disease-endemic countries) and health challenges (MDGs, non-communicable diseases, global health)
4
Based on working documents – refer to final published call text
The European Research Area (ERA)
27 EU Member States
+7 Outermost RegionsGuadeloupe, French Guiana, Martinique and Réunion (the four French overseas departments), the Canaries (Spain), and the Azores and Madeira (Portugal)
+12 Associated Countries(the EU neighbourhood countries)Albania, Bosnia and Herzegovina, Croatia, Iceland , Israel, Liechtenstein, FYR of Macedonia, Norway, Republic of Montenegro, Serbia, Switzerland, Turkey
+FP7 Third CountriesOther countries worldwide- can participate in FP7 - some can receive funding(ICPC, incl. BRICS) and othersonly exceptionally (high-incomecountries)
5
Based on working documents – refer to final published call text
• Many topics are quite broad / more bottom-up• All topics are open for Third Country Participation:
– An opportunity to involve partners from anywhere in the world– US participation is “unconditional” as in the previous calls
• Some topics targeting Specific World Regions• Some topics calling for Specific International
Cooperation Actions (so-called SICAs) Address specific issues that partner countries face or have a global
character, on the basis of mutual interest and benefit
• Programme-Level Cooperation with specific countries alignment & coordination, i.e. agreement of topics + synchronisation of
parallel calls + networking/collaboration between funded projects
International Research Collaborations
Health Topics & Funding Schemes
6
Based on working documents – refer to final published call text
For most instruments (CP-IPs, small/medium CP-FPs):Minimum number of participants: 3 from MS/ASAverage Size: large CP-IPs – €10.7 Mio /17 partners, medium CP-FP - €3.5 Mio / 10 partners, small CP-TP – €3.2 Mio / 8 partnersAverage Third Country Participation: 30% of grants, 8% of participationsAll topics are open for Third Country Participation
But: Specific International Cooperation ActionsMinimum number of participants: 2+2 (2 from MS/AS + 2 from ICPCs)Average Size: CP-SICA - €3.4 Mio / 9 partners (5+4)Third Country Participation: up to 9 from third countries! (4 in average)Third Country Participation is not limited to countries of a target region (if any)!
International Research Collaborations
Minimum requirements & funding
7
Based on working documents – refer to final published call text
e.g.: a small- or medium-scale Collaborative Project with a €6m ceiling can involve just 3 or 4 partners for only two years with a budget of €4m.
Flexibility
Some basic rules and guidelines, but:
The size of consortium (beyond min. 3)
The composition of the consortium is for the applicants to decide
The duration of the project (bottom-up)}
International Research Collaborations
Excellence driven research
8
Based on working documents – refer to final published call text
Peer Review
Equality, Fairness, Transparency
Excellence - only the bestwill get funded
International Research Collaborations
Evaluation and SelectionBasic Principles
9
Based on working documents – refer to final published call text
Bilateral Programme-level Cooperation
EU-NIH Funding Reciprocity
« European Union and NIH collaborate »published by SCIENCE on 14 Nov 2008, Vol 322, page 1048http://www.sciencemag.org/cgi/reprint/322/5904/1049b.pdf
10
Based on working documents – refer to final published call text
International Knockout Mouse Consortium(IKMC, 2007) with US, EU, Canada; http://www.knockoutmouse.org/
International Human Microbiome Consortium(IHMC, 2008) with EU, US, Japan, France, Gambia, Australia, Canada (Korea, Ireland); http://www.human-microbiome.org/
International Cancer Genomics Consortium(ICGC, 2008) with US, EU, DE, UK, FR, ES, IT, Canada, China, India, Japan, Australia, http://www.icgc.org/
International Human Epigenome Consortium(IHEC, 2010) with EU, US, Australia, possibly Canada, Japan, China, Singapore, South Koreahttp://www.epigenome-noe.net/, see also the "Human Epigenom Project" at http://www.epigenome.org/index.php
Multilateral/global Programme-level Cooperations
International Research Consortia
11
Based on working documents – refer to final published call text
All FP7 areas All Countries Third Countries(Non-EU, Non-AC)
Proposals received(N° of participations)
42’248(237’662)
6’997(14’466)
17%(6%)
Grant Agreements(N° of participations)
6’833(40’729)
958(2117)
14%(5%)
EU funding €12’701 Mio
FP7 HEALTHProposals received(N° of participations)
2315(21’829)
591(1464)
26%(7%)
Grant Agreements(N° of participations)
405(4241)
123(327)
30%(8%)
EU funding €1’606 Mio
International Research Collaborations
Some FP7 Facts & Figures
12
Based on working documents – refer to final published call text
International Research Collaborations
Third Country ProjectsAll thematic areas
13
Based on working documents – refer to final published call text
International Research Collaborations
Third Country ParticipationFP7 COOPERATION in HEALTH
239
164152
131 136
6243
5847 38 33
4975 75
5832
1734
21 22 1829 22 31
11
6647
33 31 22 20 17 16 15 12 12 11 10 9 8 8 8 7 7 6 6 6 5 5 50
50
100
150
200
250
300Evaluated
Short listed
14
Based on working documents – refer to final published call text
• Programme-Level Cooperation with:– Russia: 1.1-3 HTP Proteomics– Brazil: 1.1.4-5 Inflammatory and Autoimmune diseases– India: 2.2.1-4 Neurodegenerative paediatric diseases– India: 2.4.1-3 Cancer from Infectious Agents– Brazil: 3.4-3 Multilateral cooperation in Public Health
• Specific International Cooperation Actions: – 2.1.1-4 Pop. Genetics on Cardio-Metabolic Disorders– 2.3.3-2 Control of Dengue Fever– 2.4.3-4 Obesity and/or Diabetes in Specific Populations– 3.4-1 Reproductive Health and Health Equity
• Other topics of particular international nature: – 2.3.3-1 Zoonotic Viruses– 2.3.3-3 Major Epidemic Outbreaks– 2.3.1-2 Evolution/transfer of AMDR– 3.3-1 Determinants of Health– 3.4-2 Research Capacity
International Research Collaborations
Opportunities in the next Call (WP2011)
2.1.1-1 Human Epigenomics (IHEC) 2.1.1-3 host aspects of inf.diseases 4.1.3- Research Capacity 4.2-1 Paediatric Medicines
15
Based on working documents – refer to final published call text
Calls for Proposals, Work Programme (Topics)http://cordis.europa.eu/fp7/health/
National Contact Points (NCPs) - Information & support for applicantshttp://cordis.europa.eu/fp7/health/support_en.html
FP6/FP7 projects databaseshttp://www.lifecompetence.eu/; http://www.healthcompetence.eu/
Partner search toolshttp://www.smesgohealth.org/, http://cordis.europa.eu/fp7/partners_en.html
EU health research websitehttp://ec.europa.eu/research/health/
International Research Collaborations
Information & Support
16
Based on working documents – refer to final published call text
Other FP7 opportunitiesfor international cooperation
RTD Career, Training, MobilityMarie Curie International Incoming Fellowships (MC-IIF)http://cordis.europa.eu/fp7/mariecurieactions/iif_en.html
Marie Curie International Outgoing Fellowships (MC-IOF)http://cordis.europa.eu/fp7/mariecurieactions/iof_en.html
International Research Staff Exchange Scheme (IRSES)http://cordis.europa.eu/fp7/mariecurieactions/irses_en.html
Euraxess - Researchers in Motion, One-stop shop for researchers seeking to move to other countries (Job Portal, Mobility Services, Networks)http://ec.europa.eu/euraxess/index.cfm
RTD CapacitiesAccess to Research Infrastructureshttp://ec.europa.eu/research/infrastructures/index_en.cfm?pg=ri_projects_fp7
17
Based on working documents – refer to final published call text
Proposed topics for 2011 WPwith an
international dimension or focus
18
Based on working documents – refer to final published call text
Biotech, tools & technologies
1.1 – High-throughput research
1.1-3 High-throughput proteomics for human health and disease.Funding scheme: collab. project, max €3m, single-stage, one or more proposals.Target Regions: EU, Eastern Europe & Central Asia (EECA), esp RussiaProgramme-level Cooperation with Russia
1.4-5 New therapeutic approaches in chronic inflammatory and autoimmune diseases. Funding scheme: collab. project, max €3m, single-stage, one or more proposalsProgramme-level Cooperation with Brazil
Int
1.4 – Innovative therapeutic approaches and interventions
Int
19
Based on working documents – refer to final published call text
Translating research for health
2.1.1 – large-scale data-gathering:
2.1.1-1 High impact initiative on the human epigenome. Funding scheme: collab. project, max €30m, single-stage, max one proposal.Cooperation with Int. Human Epigenomics Consortium (IHEC)
2.1.1-3 Large-scale genomics approaches to identify host determinants of infectious diseases. Funding scheme: collab. project, max €12m, single-stage, max one proposal.
2.1.1-4 Population genetic studies on cardio-metabolic disorders in EU/AC and EECA populations. Funding scheme: Specific International Cooperation Action (SICA), collab. project, max €6m, single-stage, max one proposal.Target Regions: EU/AC, Eastern European & Central Asian Countries (EECA)
Int
20
Based on working documents – refer to final published call text
Translating research for health
2.2.1 – Research on the Brain and related diseases, human development and ageing:
2.2.1-4 Creating clinical and molecular tools for experi-mental therapy of paediatric neurodegenerative disorders causing childhood dementia in Europe and India. Funding scheme: collab. project, max €3m, single-stage, one or more proposals.Target Regions: EU & IndiaProgramme-level cooperation with India
2.3-1 Anti-microbial drug resistance
2.3.1-2 Multi-disciplinary research on the evolution and transfer of antibiotic resistance. Funding scheme: collab. project, max €12m, single-stage, max one proposal.
Int
21
Based on working documents – refer to final published call text
Translating research for health
2.3.3 – Potentially new and re-emerging epidemics
2.3.3-1 Identification of factors promoting the emergence of pathogens with human pandemic potential from pathogens with a zoonotic background and related prevention strategies. Funding scheme: collab. project, max €12m, two-stage, max one proposal.
2.3.3-2 Comprehensive control of Dengue fever under changing climatic conditions.Funding scheme: SICA - collab. project, max €6m, single-stage, one or more proposalsTarget regions: Latin America & Asia
2.3.3-3 Development of an evidence-based behavioural and communication package to respond to major epidemic outbreaks.Funding scheme: collab. project, max €2m, 2-stage, one or more proposals.
Int
22
Based on working documents – refer to final published call text
Translating research for health
2.4.1 – Cancer
2.4.1-3 Epidemiology and aetiology of infection-related cancersFunding scheme: collab. project, max €3m, 1-stage, one or more proposals.Programme-level cooperation with India
Int
2.4.3 – Diabetes and obesity
2.4.3-4 Genetic and environmental factors in obesity and/or diabetes in specific populations. Funding scheme: SICA – collab. project, max €3m, 2-stage, one or more proposals.Target regions: Africa, Asia, Latin America, Mediterranean countriesProgramme-level cooperation with Mexico, Australia, New Zealand
Int
23
Based on working documents – refer to final published call text
Translating research for health
2.3.4 – Neglected infectious diseases
Closed in 2011
2.3.2 – HIV/AIDS, malaria and tuberculosis
Closed in 2011
24
Based on working documents – refer to final published call text
Optimising delivery of healthcare
3.3 – Health promotion
3.3-1 Developing methodologies to reduce inequities in the determinants of health. Funding scheme: collab. project, max €3m, 2-stage, one or more proposals.
3.4 – International public health & health systems
3.4-1 Development and assessment of comprehensive and integrated interventions and programmes to improve repro-ductive health and health equity. Funding scheme: SICA - collab. project, max €3m, single-stage, one or more proposalsTarget Region: ICPC (low- & middle-income countries)
Int
25
Based on working documents – refer to final published call text
Optimising delivery of healthcare
3.4 – International public health & health systems
3.4-2 Building sustainable capacity for research for health and its social determinants in low and & middle income countries. Funding scheme: CA, max €2m, single-stage, one or more proposals.Target Region: ICPC (low- & middle-income countries)
3.4-3 Multilateral cooperation between Europe, Africa and Latin America on public health and health services research. Funding scheme: CA, max €2m, single-stage, max one proposal.Target Regions: EU, Africa, BrazilProgramme-level cooperation with Brazil
Int
Int
26
Based on working documents – refer to final published call text
Actions across the Health theme4.1 – Coordination and support actions across the theme
4.1-3 Linking EU and Latin American policy-making institutions in the field of health research.Funding scheme: CA, max €2m, single-stage, max one proposal.Target Region: EU & Latin America
4.2 – Responding to EU Policy needs
4.2-1 Investigator-driven clinical trials on off-patent medicines for children. Funding scheme: collab. project, max €6m, single-stage, one or more proposals.
CT
Int